NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.
The study, titled “Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” was recently published in Blood and focuses on acute myeloid ...
Two scientists describe how an acute myeloid leukemia diagnosis underscores the need for continued federal support for research and access to care.
Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, ...
Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 M ...
Title: ATNM-400 is a novel Actinium-225 antibody radioconjugate with strong efficacy in preclinical models of prostate cancer ...
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to ...
StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report published on Wednesday. The brokerage issued a sell rating on the stock. Ayala Pharmaceuticals ...
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback